Background: Reactivation of hepatitis B virus (HBV) during or after chemotherapy is a serious complication of cancer treatment. Guidelines suggest hepatitis B testing prior to the initiation of CD20 based therapies. Black box warnings mandate clinicians screen patients for HBV before starting immunosuppressive therapy due to the risk of hepatitis B reactivation. We conducted a workflow implementation change at our infusion center sites to improve hepatitis B serological testing in patients receiving CD20 agents at our cancer center. Methods: For baseline evaluation, patients at The University of Arizona Cancer Center who were treated with CD20 agents between the years 2013 to April 2014 were retrospectively evaluated for HBV serology results prior to the initiation of first treatment. We implemented a pharmacy and nursing workflow process regarding chemotherapy orders and lab testing through the integrated EMR technology. Presence of Hepatitis B Surface Antigen (HBsAg) and Hepatitis B Core Antibody (HBcAb) were considered complete; absence of all 2 was ‘not done’ with remaining being incomplete. We focused on improving our screening process during our analysis post-intervention from April 2014 to November 2017. Results: In our baseline study, 35% (n = 17) out of 48 patients had been tested for hepatitis B for hematologic malignancies. Post-implementation yielded 89 patients with 63 lymphoma patients, and 11 leukemia and 15 other hematological-associated diagnosis. Ninety one percent (n = 81) had been tested post-implementation for Hepatitis B labs prior to starting CD20 treatment. No Hepatitis B reactivation was identified in either study arms. Conclusions: Prior to implementation less than 35% of our patients were tested and our implementation process more than doubled our testing percentages to 91%. This process allows for an integrated workflow between pharmacy and nursing to mitigate required lab testing for CD20 agents in hematologic malignancies. The utilization of this workflow process is now being implemented with other CD20 agents for non-oncologic diagnosis.